Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Labetalol is a non-selective beta-adrenergic receptor antagonist (beta blocker) with additional selective alpha-1 adrenergic receptor blocking activity. It is used primarily to treat hypertension (high blood pressure), including hypertensive emergencies and high blood pressure in pregnancy. Labetalol works by relaxing blood vessels and slowing the heart rate, which improves blood flow and decreases blood pressure. Its mechanism of action involves competitive antagonism at both beta-1, beta-2, and alpha-1 adrenergic receptors, leading to decreased peripheral vascular resistance without significant alteration of heart rate or cardiac output. Labetalol is available as oral tablets or intravenous injection[1][2][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on labetalol.